Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2025-12-26 @ 1:23 AM
Study NCT ID:
NCT06357533
Status:
RECRUITING
Last Update Posted:
2025-10-27
First Post:
2024-04-05
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-11
Start Date Type:
ACTUAL
Primary Completion Date:
2028-04-24
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-05-24
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-05
First Submit QC Date:
None
Study First Post Date:
2024-04-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-24
Last Update Post Date:
2025-10-27
Last Update Post Date Type:
ESTIMATED